Shanghai Henlius Biotech, Inc. announced that the new drug application for new indication of HANSIZHUANG in combination with drugs containing fluorouracil and platinum for the first-line treatment of patients with PD-L1 positive unresectable locally advanced/recurrent or metastatic ESCC, has been approved by the NMPA, providing a new treatment option for patients with ESCC.
